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Summary Unlimited proliferation in immortalized cells is believed to be highly dependent on the activity of telomerase, a ribonucleoprotein
that synthesizes telomeric repeats onto chromosome ends. Using a polymerase chain reaction-based telomeric repeat amplification protocol
(TRAP) assay, we analysed telomerase activity in 99 benign and 45 malignant brain tumours. The TRAP assay results were quantitated by
normalizing the telomerase activity of each specimen to that of human glioma cell line T98G to obtain the relative telomerase activity.
Telomerase activity was also assessed visually from the autoradiograms as being positive or negative. One hundred and sixteen tumours with
negative telomerase activity had null relative telomerase activity, whereas 28 tumours with positive telomerase activity had relative
telomerase activities of 12-84.3% (mean 0% vs 36.1 ± 19.3%, P < 0.0001). Thus, quantification of telomerase activity confirmed the results
of the visual evaluation of telomerase activity on autoradiograms. Based on the assessment, malignant brain tumours had a higher positive
rate of telomerase activity than benign tumours (57.8% vs 2.0%, P < 0.001). These data indicate that positive telomerase activity is strongly
associated with malignant brain tumours and is rather rare in benign tumours, such as neurinomas or meningiomas.
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Telomeres are specialized structures that are located at the ends of
chromosomes in eukaryotes and have been highly conserved
throughout evolution (Blackburn, 1991; Greider and Blackburn,
1996). In vertebrates, telomeres consist of tandem hexameric
repeats of the sequence TTAGGG (Morin, 1989). Telomeres in
somatic tissue lose about 50-200 nucleotides with each cell divi-
sion. This shortening oftelomeres has been proposed to serve as a
mitotic clock (Harley, 1991).
The ribonucleoprotein enzyme telomerase is a type of cellular
reverse transcriptase that uses the template region of the RNA
moiety complementary to the TTAGGG repeat to synthesize one
strand of telomeric DNA. This synthesis of telomeric repeats
compensates for the gap remaining at the 5' ends ofeach daughter
strand (the end-replication problem) (Greider and Blackburn,
1985; Morin, 1989). In most human somatic cells, gradual telom-
eric shortening resulting from cell division does not reactivate
telomerase. In contrast, telomeres in germ line cells and in immor-
talized cells, such as cancer cells, are continuously extended by
telomerase to compensate for the loss of telomeric repeats
(Counter et al, 1992).
Over the past few years, numerous studies have shown that
telomerase is expressed and active in various types of tumours
(Kim et al, 1994; Chadeneau et al, 1995; Hiyama E et al, 1995a
and b; Piatyszek et al, 1995; Tahara et al, 1995; Ohyashiki et al,
1996; Sommerfeld et al, 1996). In one study, telomerase activity
was detected in 90 of 101 human tumour samples (representing 12
tumour types) but in none of 50 samples of normal somatic tissue
(representing four tissue types) (Kim et al, 1994). In a more recent
study of90 glial tumours, telomerase activity was detected in 75%
of glioblastomas and in all oligodendrogliomas, but only 10% of
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1995). In all of those studies, however, telomerase activity was
analysed qualitatively by assessment of the autoradiograms as
either positive or negative. In this study, we quantified the telo-
merase activities of 144 human brain tumours of various types
using the polymerase chain reaction (PCR)-based telomeric repeat
amplification protocol (TRAP) assay and compared the results
with those of qualitative visual assessment of telomerase activity.
Our findings indicate that positive telomerase activity is strongly




Brain tumour samples were obtained from 144 patients (aged 1-81
years) who underwent surgical treatment in our university hospital
between January 1992 andJuly 1996. All 144 specimens were histo-
logically diagnosed. No procedures were performed solely for
research purposes. The samples were frozen immediately after
removal and stored at - 80°C. Human glioma cell line T98G and
CB57BL/6 mouse ovarian tissue were used as positive controls. The
histological diagnoses ofthe brain tumours are summarized in Table
1. Ninety-nine ofthe tumours were benign and 45 were malignant.
TRAP assay
Telomerase activity was detected with the TRAP assay (Kim et al,
1994; Piatyszek et al, 1995; Wright et al, 1995; Ohyashiki et al,
1996). In brief, lysates were prepared from 1 x 104 cells and treated
with ice-cold detergent lysis buffer [0.5% CHAPS (3-cholamido-
propyl-dimethylammonio-1-propanesulphonate; Pierce, Rockford,
IL, USA), 0.5 mm 2-mercaptoethanol (Sigma, StLouis, MO, USA),
0.1 mm phenylmethylsulphonyl fluoride (Wako, Osaka, Japan)],
incubated on ice for 30 min and centrifuged at 10000g for 30 min
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at 4°C. The supernatant was stored at - 80°C. Each brain tumour
sample was also treated with ice-cold detergent lysis buffer. The
concentration of protein was measured with the BCA protein
assay kit (Pierce). The integrity of the protein of each sample
was confirmed by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis.
The TRAP assay consisted of two reactions. For the first reac-
tion (telomeric extension by telomerase), cell extracts (4 jg) were
incubated with the TRAP reaction mixture [50 gM dNTPs (Takara,
Ohtsu, Japan), 2 units of Taq polymerase (Takara), 5 x 105 c.p.m.
of C32P-labelled dCTP (Amersham, Bucks UK), 0.25 gM T4 gene
32 protein (Boehringer Mannheim, Mannheim, Germany) and
TS primer (5'-AATCCGTCGAGCAGAGTT-3')] at room temper-
ture for 30 min. The mixture was then incubated at 90°C to inacti-
vate the telomerase. For the second reaction (PCR amplification),
CX primer (5'-(CCCTTA)3CCCTAA-3') was sequestered by a
wax barrier (AmpliWax; Perkin-Elmer, Melbourne, Australia),
and the mixture was subjected to 27, 30 or 34 PCR cycles at 94°C
for 30 s, 50°C for 30 s and 72°C for 90 s. PCR products were
analysed by electrophoresis in 0.5 x Tris-borate EDTA on 8%
polyacrylamide denaturing gels. The gels were dried, processed
for autoradiography and exposed at - 80°C for 6 h (X-OMAT AR
film; Eastman Kodak, Rochester, NY, USA). Incremental 6-bp
ladders were visualized if the specimen was telomerase positive.
Each sample was assayed in duplicate.
As a control for the determination ofassay specificity, extracts of
telomerase-positive tissue specimens were pretreated with RNAase
to abolish telomerase activity (data not shown). To identify speci-
mens that were non-informative because Taq polymerase inhibitors
affected the TRAP assay, an internal standard (a kind gift from DrL
Gollahon and Professor J Shay, University of Texas, Southwestern
Medical Center, Dallas, TX, USA) was used that consisted of a
nucleotide including sequences encoding the TS and CX primers
and amino acids 97-132 of rat myogenin (Wright et al, 1995). The
internal standard (15 attograms per reaction) was added to the PCR
mixture and was competitively amplified by Taq polymerase.
Qualitative evaluation of telomerase activity
The telomerase activity ofeach tumour sample was visually evalu-
ated from the autoradiograms as either positive or negative by two
independent examiners.
Table 1 Histological diagnosis and telomerase activity in 144 brain tumours
Histological diagnosis Malignancy Visually positive telomerase activity Relative
(positive/no. of samples) (%) telomerase activity (%)a
Glial tumours (n = 19) 5/19 (26)
Astrocytoma grade 2 B 0/8 All 0
Ependymoma B 0/2 All 0
Anaplastic astrocytoma M 0/3 All 0
Glioblastoma multiforme M 3/6 (50) 22.2, 22.9, 86.0; Others 0
Meningeal tumours (n = 44) 3/44 (7)
Primary B 0/34 All 0
Recurrent B 2/3 (67) 42.0, 72.0, 0
Atypical M 1/5 (20) 16.4; Others 0
Haemangiopericytoma M 0/1 0
Malignant meningioma M 0/1 0
Neurinoma (cranial nerve origin; n = 43)b B 0/43 All 0
Metastatic brain tumours (n = 16) M 13/16 (81) 16.7, 20.0, 21.7, 25.3,
27.1, 28.6, 34.6, 38.0,
40.0, 41.0, 58.1, 59.0,
73.6; Others 0
Malignant lymphoma (n = 3) M 2/3 (67) 17.3, 84.3, 0
Miscellaneous tumours (n = 19) 5/19 (26)
Haemangioblastoma B 0/5 All 0
Teratoma B 0/1 0
Paraganglioma B 0/1 0
Pituitary adenoma B 0/1 0
Cortical dysplasia B 0/1 0
Primitive neuroectodermal tumour M 0/1 0
Medulloblastoma M 2/2 (100) 12.0,17.3
Malignant chordoma M 1/2 (50) 44.5, 0
Ewing's sarcoma M 2/2 (100) 41, 37.3
Chondrosarcoma M 0/1 0
Leiomyosarcoma M 1/1 (100) 41.0
Malignant melanoma M 1/1 (100) 16.9
Overall results
Benign tumours 2/99 (2.0)
Malignant tumours 26/45 (57.8)
an this study, relative telomerase activity was defined as negative when it was less than 3%. bIncludes five cases of neurofibromatosis type 2. B, benign; M,
malignant.
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Figure 1 Relationship between lysate concentration and relative telomerase
activity. The telomerase activity of human glioma cell line T98G was analysed
in tenfold serial dilutions of cell extracts for 27, 30 or 34 PCR cycles. Only
when 27 PCR cycles were used was there a nearly linear correlation between
lysate concentration and relative telomerase activity
Measurement of relative telomerase activity
We quantified the TRAP assay results by normalizing the signal
density ofeach ladder to that ofhuman glioma cell line T98G as a
positive control. The signal density of each ladder was measured
from the lowest to the tenth band individually and integrated with
photoimaging software (NIH Image; National Institutes of Health,
Bethesda, MD, USA) and a Macintosh personal computer (Apple
Computer, Cupertino, CA, USA). The sum of each lane was used
as the value for telomerase activity. Relative telomerase activity
was calculated as the density ofthe ladders divided by the density
ofthe positive control (T98G).
Statistical analysis
Results are expressed as the mean ± s.d. Statistical analyses were
performed using the statistical analysis system (SAS Institute,
Cary, NC, USA).
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RESULTS
Qualitative telomerase activity
The qualitative visual analysis of autoradiograms of 144 brain
tumours showed that 28 tumours were positive for telomerase
activity whereas 116 were negative (Table 1).
Relative telomerase activity
Telomerase activity was quantitated in human glioma cell line
T98G. Cell extracts representing 104, 103, 102 and 101 cell equiva-
lents were subjected to 27, 30 or 34 PCR cycles. The relative telom-
erase activity was almost linearly proportional to the concentration
oflysate only when 27 PCR cycles were used (Figure 1). Therefore,
and as originally recommended (Kim et al, 1994; Piatyszek et al,
1995), the TRAP assay was performed with 27 PCR cycles.
The relative telomerase activities in the 144 brain tumour
samples, including 19 glial tumours, 44 meningeal tumours, 43
neurinomas and 16 metastatic brain tumours, are summarized in
Table 1. All 28 tumours with visually positive telomerase activity
had relative telomerase activities greater than 12%, whereas all 116
tumours with visually negative telomerase activity had null relative
telomerase activity. The mean relative telomerase activities in
the two groups were significantly different (36.1 ± 19.3% vs 0%,
P < 0.0001, Mann-Whitney's U-test). Of six glioblastomas, three
had positive relative telomerase activities of 22.2-89%, and three
had no activity. Anaplastic astrocytomas and ependymomas had
null relative telomerase activity. Of 44 meningeal tumours, only
one atypical and two recurrent meningiomas had relative positive
telomerase activities (42%, 72% and 16.4% respectively). None of
43 neurinomas had positive relative telomerase activity. Relative
telomerase activities for the three malignant lymphomas were
84.3%, 17.3% and 0%. Among 19 miscellaneous tumours, two
medulloblastomas, three of four sarcomas, one of two malignant
chordomas and one malignant melanoma had relative telomerase
activities of 12-44.5%. The other miscellaneous tumours had null
relative telomerase activity. Thirteen of 16 metastatic brain tumours











Figure 2 TRAP assay of brain tumours of various histological types. A 4-pg volume of tissue extract was analysed in each assay. Lane 1 was negative control
(lysis buffer only). Lanes 2, 3 and 4 were astrocytoma grade 2, astrocytoma grade 3 and glioblastoma multiforme respectively. Glioblastomas showed a high
level of telomerase activity. Lanes 5 and 6 were meningiomas. Lane 7 was a neurinoma. Most meningiomas and all neurinomas showed no telomerase activity.
Lanes 8 and 9 were metastatic brain tumours. Lane 10 was a malignant lymphoma. Lane 11 was a Ewing's sarcoma. These malignant tumours had high levels
of telomerase activity. Lanes 12 and 13 were positive controls (CB57BU6 mouse ovary and human glioma cell line T98G). Pretreatment of extracts with
RNAase abolished telomerase activity in telomerase-positive tissues and provided the control for the determination of assay specificity (data not shown).
Internal control signals were identified in all surgical specimens. This figure shows ladders of 58 base pairs or larger
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TRAP assay results for tumours ofvarious histological types are
shown in Figure 2. Signals from the internal standard were identi-
fied in all specimens. Overall, malignant brain tumours exhibited a
higher rate oftelomerase positivity than benign tumours [26 of45
(57.8%) vs 2 of 99 (2.0%); P < 0.001, chi-square analysis].
DISCUSSION
In this study, analysis of telomerase activity in 144 brain tumour
specimens with a PCR-based TRAP assay showed that malignant
tumours had a higher rate of telomerase positivity than benign
tumours (57.8% vs 2.0%; P < 0.001). This difference in telom-
erase positivity rates between malignant and benign tumours is
adequate for estimating immortality and malignancy.
Although relative telomerase activity of some systemic cancers
has been evaluated by dilution analysis (Hiyama E et al, 1995a and
b; Hiyama K et al, 1995); Tahara et al, 1995) and has even been
semiquantified by several investigators (Taylor et al, 1996), the
telomerase activity of tumour tissues has mostly been assessed
visually as being either positive or negative (Kim et al, 1994;
Chadeneau et al, 1995; Langford et al, 1995; Piatyszek et al, 1995;
Sommerfeld et al, 1996). To justify the visual, 'all-or-nothing'
evaluation of telomerase activity, we quantified the TRAP assays
of brain tumours and compared the results with visually deter-
mined positivity. In one semiquantitative analysis of relative
telomerase activity in skin cancers (Taylor et al, 1996), the telo-
merase activity of the specimen was normalized to that of the
internal standard, used as a positive control. However, because the
PCR reaction in the TRAP assay is a competitive reaction between
TS primers and the internal standard, the intensity of the internal
standard is not a fixed index; rather, it is inversely proportional to
the intensity of specimen. For this reason, the internal standard is
not suitable as a positive control. Therefore, we defined relative
telomerase activity as the density of ladders divided by the density
ofthe positive control -T98G, a fully immortalized human glioma
cell line that expresses consistent telomerase activity (Langford et
al, 1995). Relative telomerase activity for another established stan-
dard cell line, 293, is 92.2%. Relative telomerase activity can thus
indicate quantitative levels of telomerase activity. Our results
demonstrate a significant difference in relative telomerase activi-
ties between telomerase-positive and telomerase-negative tumours
(36.1 ± 19.3% vs 0%, P < 0.0001). These data clearly justify the
visual assessment of telomerase activity from autoradiograms.
In glial tumours, three (50%) of six glioblastomas (grade 4), but
no astrocytomas (grade 2) or anaplastic astrocytomas (grade 3),
were telomerase positive in our study. Similarly, in Langford's
study of 90 glial tumours, 75% ofglioblastomas, but only 10% of
anaplastic astrocytomas, were telomerase positive (Langford et al,
1995). These findings suggest that telomerase contributes to the
malignant progression of glial tumours.
Malignant non-glial brain tumours also exhibited high levels of
telomerase activity. Metastatic brain tumours had a high rate of
telomerase positivity (13 of 16; 81%) and high levels of relative
telomerase activity (range 16.7-73.6%; mean 30.2%). Sarcomas
also had a high positivity rate (three of four; 75%) and high levels
of relative telomerase activity (37.3%, 41% and 41%).
In contrast, among benign, non-glial tumours, such as menin-
giomas and neurinomas, only two, both recurrent meningiomas,
exhibited positive telomerase activity. Although they generally
appeared to be histologically benign, both displayed malignant
phenotypes, such as rapid growth. Our study may thus be the first
to report null telomerase activity of such benign brain tumour
populations.
Telomerase activity was undetectable in 46.9% ofthe malignant
brain tumours we studied, whereas more than 80% of systemic
tumours exhibit telomerase activity (Chadeneau et al, 1995;
Hiyama E et al, 1995a; Tahara et al, 1995). This difference may be
explained by the following reasons. The first reason arises from
the distinct nature ofbrain tumours. Compared with most systemic
cancers, primary brain tumours are not histologically malignant
(Vick, 1992) and often result in neurological disorders (e.g. focal
signs and epilepsy) before causing a mass effect. In addition,
recent advances in neuroimaging techniques have made it possible
to detect very small lesions that lack populations ofimmortal cells
and are telomerase negative. Therefore, some of the tumours we
studied may have been removed before any of their cells acquired
immortality. In contrast, the telomerase positivity rate of
metastatic brain tumours was as high as that of primary cancers
(Chadeneau et al, 1995; Hiyama E et al, 1995b; Hiyama K et al,
1995; Tahara et al, 1995; Sommerfeld et al, 1996). This is because
metastatic brain tumour cells have already become immortal at
their primary lesion stage. The second reason concerns the possi-
bility of an alternative mechanism of immortalization in brain
tumour cells. Langford et al (1995) found that some anaplastic
astrocytomas with malignant potential showed no telomerase
activity and suspected an alternative mechanism of maintaining
telomere length. Bryan et al (1995) recently described a telom-
erase-independent mechanism in an immortalized human cell line
without detectable telomerase activity. The third reason relates to
the sensitivity of our assay. We used photoimaging software to
quantify the TRAP assay, and the relative telomerase activity
could not be estimated if telomerase activity was less than 3%.
PCR is a powerful tool for amplifying small amounts of oligo-
nucleotides. But, when we used 30 or 34 PCR cycles in the TRAP
assay, the density ofladders did not correlate well with the concen-
tration of the lysates. As a result, we limited the number of PCR
cycles to 27 for measurement ofrelative telomerase activity in this
assay. As a result, very low levels of telomerase activity may not
have been detected.
Our results indicate that brain tumours of the same histological
classification do not always show the same relative telomerase
activity. One reason for this discrepancy is the heterogeneity of
tumour cell populations in terms of immortality: some tumours
contain only a small portion of immortal cells, whereas others
contain aclonally expanded population ofimmortal cells. Even the
level of relative telomerase activity in each immortalized cell in
tumour tissue may differ from cell to cell. Further study is required
to clarify which tumour phenotypes, such as growth rate, resis-
tance to chemotherapy or radiation therapy, and naturally occur-
ring apoptosis rate, are affected by the level of relative telomerase
activity and whether among telomerase-positive malignant
tumours the relative telomerase activity correlates with the grade
of malignancy. Nevertheless, positive telomerase activity is a
potent indicator of malignant brain tumours.
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